NKTR Stock Chart & Stats
$1230.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1230.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$165.00 - $1,742.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$41.70B
Enterprise Value$1.35K
Total Cash (Recent Filing)$568.60M
Total Debt (Recent Filing)$143.43M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Aug 13, 2026EPS Estimate
-34.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.42
Shares Outstanding33,786,034
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)7.94
Price to Sales (P/S)12.91
P/FCF Ratio-3.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,691.28Price Target Upside118.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-155.58
Revenue Forecast (FY)$719.77M
Bulls Say, Bears Say
Bulls Say
Clinical Validation (REZPEG Phase IIb)Durable Phase IIb efficacy reduces scientific risk ahead of registrational studies. Persistent and deepening responses support the planned Phase III designs, strengthen regulatory discussions, and increase the odds of approval or partner interest, underpinning long-term commercial opportunity.
Liquidity And RunwayPro‑forma cash >$1B and a runway into Q3 2028 materially reduces near‑term financing pressure and gives the company flexibility to fund Phase III programs, enrollment and regulatory activities without immediate dilution, supporting sustained clinical execution.
Differentiated Safety And MechanismA favorable safety profile versus JAKs and a distinct Treg‑stimulating MOA can be a durable competitive advantage for chronic indications. Lower monitoring burdens and better tolerability support broader uptake and longer treatment durations, improving sustained market positioning.
Bears Say
Cash Generation WeaknessSustained negative operating and free cash flow (~-$204M TTM) means the business fundamentally relies on financing or reserves to fund operations. As Phase III spends ramp, persistent burn raises financing, dilution and runway risks that materially affect strategic choices.
Ongoing Losses And Rising R&D SpendLarge and recurring net losses with planned higher R&D as Phase IIIs start mean profitability is distant. Increased expense commitments will deepen operating deficits and pressure the balance sheet absent sustained milestone revenue or additional capital, constraining long‑term financial flexibility.
Execution And Enrollment RiskLarge global pivotal programs (~150 sites/study) introduce structural execution risk: site activation, CRO management, and multi‑region enrollment can delay readouts, inflate costs, or affect data quality. These operational risks directly influence approval timing and commercial timelines.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $165.00 and its highest was $1742.00 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $41.70B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 13 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on May 07, 2026. The company reported -$31.742 earnings per share for the quarter, missing the consensus estimate of -$27.591 by -$4.151.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -34.38.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 33,786,034 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$31.742 in its last earnings report, missing expectations of -$27.591. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in MX:NKTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2,691.28 (118.80% Upside)
$2,691.28 (118.80% Upside)
Blogger Sentiment
Bullish
MX:NKTR Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $42.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
187.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
197.87%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
NKTR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivered strong clinical progress and a clear, accelerated path to Phase III for REZPEG in atopic dermatitis and alopecia areata, supported by robust Phase IIb data (durable and deepening responses, EASI‑100 increases, SALT‑20 gains) and a fortified balance sheet (> $1B pro forma). Key positives include well‑defined Phase III designs, meaningful market opportunity, favorable safety signals versus JAK inhibitors, and additional pipeline and TrialNet collaboration in type 1 diabetes. Main concerns are typical biotech risks: ongoing net losses and increasing R&D spend as Phase III programs start, noncash interest expense, remaining regulatory/endpoint design questions (especially for AA and potential moderate AA expansion), and operational enrollment/execution risk for global trials. On balance, the positives (clinical validation, financing, program advancement) outweigh the near‑term financial and execution risks.View all MX:NKTR earnings summariesNKTR Stock 12 Month Forecast
Average Price Target
$2,691.28
▲(118.80% Upside)